Selskabets formål er at udvikle, producere og sælge produkter til brug inden for området for human reproduktion og cellekulturer og anden dermed forbunden virksomhed efter direktions skøn.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 760.8 mio. | 4.9 mio. | 443.3 mio. | 171.7 mio. | 107 | |
CVR: 10975077
Secondary names: MEDI-CULT A/S, MEDICULT A/S, ORIGIO SCANLAB EQUIPMENT A/S
Previous names: ApS KBUS 8 NR. 2546, MEDI-CULT A/S, MEDICULT A/S
Compared to 998 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Companies in the same industry and area
CVR 37010839
CVR 17988433
CVR 27489524
CVR 10021065
CVR 41493704
The financial health of ORIGIO A/S shows a concerning downward trajectory, with revenue declining from 932 million DKK in 2023 to 760 million DKK in 2025, while profits have significantly dropped from 29 million DKK to just under 5 million DKK in the same period. After experiencing a substantial loss in 2022, the company has struggled to regain profitability, indicating potential operational challenges. Equity has decreased from 316 million DKK in 2023 to 171 million DKK in 2025, raising concerns about financial stability and resilience. Despite being positioned in the research and experimental development sector, the declining margins and equity suggest that ORIGIO A/S may need to reassess its strategies to improve its market standing and financial performance.
AI-generated summary
companydata.dk